OcellO news

23 August 2016- OcellO partners in NC3R-funded collaboration with Kings College to develop in vitro animal alternatives to patient derived mouse xenograft models of breast cancer.

OcellO partners in NC3R-funded collaboration with Kings College to develop 3D in vitro screening models to simulate patient derived xenograft mouse models of breast cancer. The collaboration with Prof. Andrew Tutt and Dr Rebecca Marlow, from Kings College London is valued at GBP 355,000 and will focus on the particularly aggressive ‘triple negative’ breast cancer subtype.
In the project, a panel of 3D in vitro models from tumour tissue from The KCL PDX collection will be developed and validated with standard of care therapies.  These models will be added to OcellO’s portfolio of 3D tumour models and offered for fee-for-service screening.
See the link to the NC3R webstite for more details.

OcellO announces strategic outsourcing agreement with Synthon Biopharmaceuticals for compound testing in patient-derived tumour models

December 15th, 2015 – Leiden, The Netherlands


OcellO today announced continuation of the collaboration in discovery projects with Synthon Biopharmaceuticals whereby OcellO will provide services for high-content screening in patient-derived in vitro tissue models. OcellO will use panels of patient-derived 3D tumour models for testing of Synthon’s antibody-drug conjugates for its preclinical oncology research programs.


Patient-derived 3D tumour cultures bridge the gap between conventional cell line derived in vitro models and in vivo models. Furthermore, OcellO’s image-based analysis of 3D tissues provides more detailed insight into the effects of ADCs on tumour tissues compared to conventional growth and killing assays.


“The collaboration with Synthon builds on an earlier successful project and is an important recognition of the added value of our screening technology for the pre-clinical evaluation of drug performance.  This is a great opportunity to apply our human tissue models to the development of state-of-the-art therapeutic molecules for the improvement of cancer treatment”, said Leo Price, CEO of OcellO.


Marco Timmers, CSO of Synthon, commented: “We are very excited about our partnership with OcellO. It allows Synthon to benefit from OcellO’s leading position in tissue based screening, which we expect will be beneficial for a number of projects in our pipeline”.


OcellO is a CRO that offers drug screening and profiling services using 3D cell culture models of cancers and other diseases. OcellO uses high-content 3D imaging and analysis to measure drug effects, extracting clinically relevant information on compound effects.  For more information, contact Leo Price (Leo.Price@OcellO.nl) or visit the website (www.OcellO.nl).

5 august 2015 – New publication in Molecular Cancer on identification of anti-tumour biologics using OcellO’s platform

5 August 2015 –  A new publications on the application of OcellO’s platform to identify anti-tumour biologics for MedImmune has been published in the journal Molecular Cancer.

The article describes how a phenotypic antibody screen with 3D cultures of primary cells and image based multi-parametric profiling was used to identify anti-cancer biologics against new therapeutic targets.

Click here for the article

June 18th 2014: TomTom co-founder navigates into biotech with investment in OcellO

€0.5 million funding will expand use of 3D tissue mapping in drug discovery

Leiden, The Netherlands, 19th June 2014 – Leiden-based biotechnology company OcellO has entered into a strategic partnership with TomTom founder and philanthropist Pieter Geelen to further develop its biological ‘mapping’ technology and fund the next stage of growth in its drug discovery screening services.

Continue reading →

May 27th 2013: OcellO expands 3D screening activities in 6 million Euro partnership

OcellO to partner in € 6 Millon FP7 grant to develop therapeutic antibodies targeting Cancer Stem Cells Using its 3D screening platform with patient-derived “Organoids”.

Leiden, The Netherlands, May 27th, 2013 – OcellO B.V. a contract research company that exploits an innovative 3D culture-based screening platform, today announced that it has been granted funding from the European Union’s FP7 program. The suppresSTEM consortium, which is led by the antibody discovery company, Merus, has been granted a total of about €6 M to develop patient-derived Organoid-based screening tools and discover novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer. The consortium also includes The Hubrecht Institute (The Netherlands), Fundacio Privada Institut de Recerca Biomedica (Spain) and The Wellcome Trust Sanger Institute (UK).
Continue reading →

Jan 14th 2013: OcellO signs contract with Merus Biopharmaceuticals to screen genetically engineered therapeutic antibodies

OcellO and Merus sign agreement for screening bispecific cancer antibodies

Leiden and Utrecht, The Netherlands, January 14, 2013 – OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell culture-based screening platform to profile bispecific antibodies designed by Merus for the treatment of cancer. Financial details of the collaboration have not been disclosed.
Continue reading →